Chiusura precedente | 18,71 |
Aperto | 18,62 |
Denaro | 18,27 x 1200 |
Lettera | 18,28 x 1100 |
Min-Max giorno | 18,20 - 18,73 |
Intervallo di 52 settimane | 10,84 - 24,79 |
Volume | |
Media Volume | 2.351.717 |
Capitalizzazione | 4,653B |
Beta (5 anni mensile) | 0,79 |
Rapporto PE (ttm) | 4,56 |
EPS (ttm) | 3,99 |
Prossima data utili | 02 mag 2024 |
Rendimento e dividendo (futuro) | 1,12 (5,99%) |
Data ex dividendo | 23 feb 2024 |
Stima target 1A | 21,50 |
INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab). The Phase 4, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study (NCT05510063) for SB5 was conducted across 33 sites in four countries (Bulgaria, Czechia, Lithuania, Poland) from August 2022 to May 2023
Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreementSAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023. “We